TY - JOUR
T1 - Cyclosporine-induced optic neuropathy, ophthalmoplegia, and nystagmus in a patient with Crohn disease
AU - Porges, Yair
AU - Blumen, Sergiu
AU - Fireman, Zvi
AU - Sternberg, Amos
AU - Zamir, Doron
PY - 1998/1/1
Y1 - 1998/1/1
N2 - PURPOSE: To report the cyclosporine-induced complications of optic neuropathy, partial external ophthalmoplegia, and other neurologic abnormalities. METHODS: Case report. A 22-year-old man with severe active Crohn disease developed bilateral optic neuropathy, nystagmus, external ophthalmoplegia, and ataxia on the fifth day of cyclosporine A (CyA) parenteral therapy. RESULTS: Cyclosporine therapy was discontinued as soon as toxic clinical manifestations appeared. Cyclosporine blood level detected then was 1,290 ng/ml (therapeutic level: 150 to 300 ng/ml). Partial external ophthalmoplegia improved dramatically; however, the patient's optic neuropathy progressed to optic atrophy, leaving the patient visually impaired. Various possible mechanisms for cyclosporine-induced neurotoxicity are discussed. CONCLUSION: It is important to closely monitor neuro- ophthalmologic and neurologic signs of patients treated with cyclosporine.
AB - PURPOSE: To report the cyclosporine-induced complications of optic neuropathy, partial external ophthalmoplegia, and other neurologic abnormalities. METHODS: Case report. A 22-year-old man with severe active Crohn disease developed bilateral optic neuropathy, nystagmus, external ophthalmoplegia, and ataxia on the fifth day of cyclosporine A (CyA) parenteral therapy. RESULTS: Cyclosporine therapy was discontinued as soon as toxic clinical manifestations appeared. Cyclosporine blood level detected then was 1,290 ng/ml (therapeutic level: 150 to 300 ng/ml). Partial external ophthalmoplegia improved dramatically; however, the patient's optic neuropathy progressed to optic atrophy, leaving the patient visually impaired. Various possible mechanisms for cyclosporine-induced neurotoxicity are discussed. CONCLUSION: It is important to closely monitor neuro- ophthalmologic and neurologic signs of patients treated with cyclosporine.
UR - http://www.scopus.com/inward/record.url?scp=0032190006&partnerID=8YFLogxK
U2 - 10.1016/S0002-9394(98)00137-8
DO - 10.1016/S0002-9394(98)00137-8
M3 - Article
AN - SCOPUS:0032190006
SN - 0002-9394
VL - 126
SP - 607
EP - 609
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 4
ER -